MA54276A - Montélukast de traitement de l'ostéoarthrite érosive de la main - Google Patents
Montélukast de traitement de l'ostéoarthrite érosive de la mainInfo
- Publication number
- MA54276A MA54276A MA054276A MA54276A MA54276A MA 54276 A MA54276 A MA 54276A MA 054276 A MA054276 A MA 054276A MA 54276 A MA54276 A MA 54276A MA 54276 A MA54276 A MA 54276A
- Authority
- MA
- Morocco
- Prior art keywords
- montelukast
- treatment
- hand
- erosive osteoarthritis
- erosive
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 201000008482 osteoarthritis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382851 | 2018-11-26 | ||
| PCT/EP2019/082425 WO2020109230A1 (fr) | 2018-11-26 | 2019-11-25 | Montélukast de traitement de l'ostéoarthrite érosive de la main |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54276A true MA54276A (fr) | 2021-10-06 |
| MA54276B1 MA54276B1 (fr) | 2023-11-30 |
Family
ID=64665075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54276A MA54276B1 (fr) | 2018-11-26 | 2019-11-25 | Montélukast destinée au traitement de l'arthrose de la main |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220047570A1 (fr) |
| EP (1) | EP3886857B1 (fr) |
| JP (1) | JP7399502B2 (fr) |
| CN (1) | CN113347975B (fr) |
| AU (1) | AU2019386235A1 (fr) |
| BR (1) | BR112021009980A2 (fr) |
| CA (1) | CA3120920C (fr) |
| DK (1) | DK3886857T3 (fr) |
| ES (1) | ES2961390T3 (fr) |
| FI (1) | FI3886857T3 (fr) |
| HR (1) | HRP20231283T1 (fr) |
| HU (1) | HUE063579T2 (fr) |
| MA (1) | MA54276B1 (fr) |
| MD (1) | MD3886857T2 (fr) |
| MX (1) | MX2021006209A (fr) |
| PL (1) | PL3886857T3 (fr) |
| PT (1) | PT3886857T (fr) |
| RS (1) | RS64668B1 (fr) |
| SI (1) | SI3886857T1 (fr) |
| WO (1) | WO2020109230A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4228641A1 (fr) * | 2020-10-13 | 2023-08-23 | Diomed Developments Limited | Formulations de gel contenant du montélukast |
| GB2599912B (en) * | 2020-10-13 | 2023-04-19 | Diomed Dev Ltd | New formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201020085D0 (en) * | 2010-11-26 | 2011-01-12 | Xaragen Pharma Ltd | Methods and reagents for the treatment of arthritic disorders |
| AU2014360704A1 (en) * | 2013-12-02 | 2016-05-19 | Abbvie, Inc. | Compositions and methods for treating osteoarthritis |
-
2019
- 2019-11-25 PT PT198057168T patent/PT3886857T/pt unknown
- 2019-11-25 JP JP2021529734A patent/JP7399502B2/ja active Active
- 2019-11-25 HR HRP20231283TT patent/HRP20231283T1/hr unknown
- 2019-11-25 MX MX2021006209A patent/MX2021006209A/es unknown
- 2019-11-25 FI FIEP19805716.8T patent/FI3886857T3/fi active
- 2019-11-25 MD MDE20210946T patent/MD3886857T2/ro unknown
- 2019-11-25 PL PL19805716.8T patent/PL3886857T3/pl unknown
- 2019-11-25 BR BR112021009980-8A patent/BR112021009980A2/pt unknown
- 2019-11-25 WO PCT/EP2019/082425 patent/WO2020109230A1/fr active Application Filing
- 2019-11-25 CA CA3120920A patent/CA3120920C/fr active Active
- 2019-11-25 MA MA54276A patent/MA54276B1/fr unknown
- 2019-11-25 EP EP19805716.8A patent/EP3886857B1/fr active Active
- 2019-11-25 ES ES19805716T patent/ES2961390T3/es active Active
- 2019-11-25 DK DK19805716.8T patent/DK3886857T3/da active
- 2019-11-25 US US17/296,703 patent/US20220047570A1/en active Pending
- 2019-11-25 CN CN201980089991.6A patent/CN113347975B/zh active Active
- 2019-11-25 AU AU2019386235A patent/AU2019386235A1/en active Pending
- 2019-11-25 HU HUE19805716A patent/HUE063579T2/hu unknown
- 2019-11-25 RS RS20230911A patent/RS64668B1/sr unknown
- 2019-11-25 SI SI201930635T patent/SI3886857T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020109230A1 (fr) | 2020-06-04 |
| DK3886857T3 (da) | 2023-10-09 |
| FI3886857T3 (fi) | 2023-10-20 |
| JP2022508236A (ja) | 2022-01-19 |
| US20220047570A1 (en) | 2022-02-17 |
| HRP20231283T1 (hr) | 2024-02-02 |
| CN113347975B (zh) | 2024-08-30 |
| HUE063579T2 (hu) | 2024-01-28 |
| CN113347975A (zh) | 2021-09-03 |
| EP3886857A1 (fr) | 2021-10-06 |
| PT3886857T (pt) | 2023-10-25 |
| SI3886857T1 (sl) | 2023-12-29 |
| EP3886857B1 (fr) | 2023-07-26 |
| MD3886857T2 (ro) | 2023-12-31 |
| MA54276B1 (fr) | 2023-11-30 |
| RS64668B1 (sr) | 2023-11-30 |
| JP7399502B2 (ja) | 2023-12-18 |
| AU2019386235A1 (en) | 2021-07-01 |
| MX2021006209A (es) | 2021-08-11 |
| CA3120920A1 (fr) | 2020-06-04 |
| ES2961390T3 (es) | 2024-03-11 |
| PL3886857T3 (pl) | 2024-01-15 |
| CA3120920C (fr) | 2024-01-02 |
| BR112021009980A2 (pt) | 2021-08-17 |
| TW202038954A (zh) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA45192A (fr) | Traitement d'association | |
| MA45050A (fr) | Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| MA51032A (fr) | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée | |
| MA43872A (fr) | Procédé de traitement d'une glomérulopathie à c3 | |
| MA52219A (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA52253A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
| MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA51613A (fr) | Polythérapie pour le traitement ou la prévention du cancer | |
| MA47437A (fr) | Procédés de traitement d'infections fongiques | |
| MA51525A (fr) | Traitement de minéraux | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA51795A (fr) | Oligonucléotides pour moduler l'expression de tmem106b |